

研究成果の刊行に関する一覧表(平成28年度)

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年(西暦)
Kanetaka T, <u>Mori M</u> , Nishimura KI, Nozawa T, Kikuchi M, Sakurai N, Hara R, Yamazaki K, Yokota S.	Characteristics of FDG-PET findings in the diagnosis of systemic juvenile idiopathic arthritis.	Mod Rheumatol	29	1-6	[Epub ahead of print]
Hisa K, Yanagimachi MD, Naruto T, Miyamae T, Kikuchi M, Hara R, Imagawa T, Yokota S, <u>Mori M</u> .	PADI4 and the HLA-DRB1 shared epitope in juvenile idiopathic arthritis.	PLoS One.	12(2):e0171961.		2017
Mimori T, <u>Harigai M.</u> , Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Ikeuchi S, Kushimoto S, <u>Koike T</u> .	Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.	Mod Rheumatol	doi: 10.1080/14397595.2016.1265695. [Epub ahead of print] PubMed PMID: 27919207.	doi: 10.1080/14397595.2016.1265695. [Epub ahead of print] PubMed PMID: 27919207.	2016
Ishiguro N, Atsumi T, <u>Harigai M.</u> , Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, Yamanaka H.	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio study.	Mod Rheumatol.	[Epub ahead of print] PubMed PMID:27414105.	[Epub ahead of print] PubMed PMID:27414105.	2016
<u>Harigai M.</u> , Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y, Sakai R, Yamazaki H, <u>Koike T</u> , <u>Miyasaka N</u> .	Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.	Mod Rheumatol.	26(5)	642-50	2016
Takada H, Hosoya T, Kimura N, Kawahata K, <u>Kohsaka H</u> .	Successful use of rituximab in a patient with refractory thrombotic thrombocytopenic purpura complicated by polymyositis.	Scand J Rheumatol			in press
Hasegawa H, Kawahata K, Mizoguchi F, Okiyama N, <u>Miyasaka N</u> , <u>Kohsaka H</u> .	Direct suppression of auto aggressive CD8+ T cells with CD80/86 blockade in CD8+ T cell-mediated polymyositis models of mice.	Clin Exp Rheumatol			in press
Matsumoto T, Saito T, <u>Kohsaka H</u> .	A case of chronic myelomonocytic leukemia complicated with spondyloarthritis.	Mod Rheumatol			in press
Hosoya T, Iwai H, Yamaguchi Y, Kawahata K, <u>Miyasaka N</u> , <u>Kohsaka H</u> .	Cell cycle regulation therapy combined with cytokine blockade enhances anti-arthritis effects without increase of immune suppression.	Ann Rheum Dis	75(1)	253-9	2016
Kamiya M, Shane PY, Soejima M, Tohda S, <u>Miyasaka N</u> , <u>Kohsaka H</u> .	IgG4-Related Sialoadenitis with a Skin Lesion and Multiple Mononeuropathies Suggesting Coexistent Cryoglobulinemic Vasculitis.	Int Med	55(10)	1355-61	2016
Ota M, Iwai H, Imai K, Kamiya M, Yoshihashi-Nakazato Y, <u>Miyasaka N</u> , <u>Kohsaka H</u> .	Acute tubulointerstitial nephritis associated with infliximab in a patient with Crohn's disease.	Int Med	55(10)	1367-70	2016
Tomimitsu H, Ohta A, Nagai M, Nishina M, Ishihara S, <u>Kohsaka H</u> .	Epidemiologic analysis of the clinical features of Japanese patients with polymyositis and dermatomyositis.	Mod Rheumatol	26(3)	398-402	2016
Hirano F, Mizoguchi F, <u>Harigai M.</u> , <u>Miyasaka N</u> , <u>Kohsaka H</u> .	Tacrolimus was used successfully to induce remission in a patient with refractory eosinophilic granulomatosis with polyangiitis complicated by invasive aspergillosis and chronic hepatitis B.	Int J Rheum Dis			in press
Yoshihashi-Nakazato Y, Kawahata K, Kimura N, <u>Miyasaka N</u> , <u>Kohsaka H</u> .	Interferon-gamma but not interleukin-4 restrains experimental polymyositis.	Arthritis Rheumatol	68(6)	1505-10	2016
Matsuo Y, Mizoguchi F, Saito T, Kawahata K, Ueha S, Matsushima K, Yinagaki Y, <u>Miyasaka N</u> , <u>Kohsaka H</u> .	Local fibroblast proliferation but not influx is responsible for synovial hyperplasia in a murine model of rheumatoid arthritis.	Biochem Biophys Res Commun	470(3)	504-9	2016
Kusuda T, Hosoya T, Mori T, Ihara K, Nishida H, Chiga M, Sohara E, Rai T, Koike R, Uchida S, <u>Kohsaka H</u> .	Acquired Gitelman syndrome in an anti-SSA antibody positive patient with a SLC12A3 heterozygous mutation: A case report.	Int Med	55 (21)	3201-04	2016
Tagawa Y, Saito T, Takada K, Kawahata K, <u>Kohsaka H</u> .	Successful treatment of severe refractory lupus hepatitis with mycophenolate mofetil.	Lupus	25	543-46	2016
Ishiwata Y, Nagata M, Arai T, Makiishi M, Yoshikawa M, Takahashi H, <u>Kohsaka H</u> , Yasuhara M.	Effects of miconazole oral gel on blood concentrations of tacrolimus and cyclosporine: a retrospective observational study.	Ther Drug Monit	38 (6)	717-21	2016
Sasaki H, Yamazaki H, <u>Kohsaka H</u> .	A case of ANCA-associated Large Vessel Vasculitis with Multiple Saccular Aneurysms.	J Rheumatol	43 (1)	179	2016

Tanaka Y, Takeuchi T, <u>Miyasaka N</u> , Sumida T, Mimori T, <u>Koike T</u> , Endo K, Mashino N, Yamamoto K.	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.	Mod. Rheumatol.	26(1)	80-86	2016
Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, <u>Miyasaka N</u> , <u>Koike T</u> .	The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.	Ann. Rheum. Dis.	75(1)	75-83	2016
Kojima M, Nakayama T, Kawahito Y, Kaneko Y, Kishimoto M, Hirata S, Seto Y, Endo H, Ito H, Kojima T, Nishida K, Matsushita I, Tsutani K, Igarashi A, Kamatani N, Hasegawa M, <u>Miyasaka N</u> , Yamanaka H.	The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014: Utilization of GRADE approach.	Mod. Rheumatol.	26(2)	175-179	2016
Tanaka Y, <u>Harigai M</u> , Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Ishii Y, Nakajima H, Baker D, <u>Miyasaka N</u> , <u>Koike T</u> .	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study.	Mod. Rheumatol.	26(3)	323-330	2016
Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Kobayashi M, Shoji T, Togo O, <u>Miyasaka N</u> , <u>Koike T</u> .	Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis.	Mod. Rheumatol.	26(4)	473-480	2016
Tanaka Y, <u>Harigai M</u> , Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, <u>Miyasaka N</u> , <u>Koike T</u> , Baker D, Ishii Y, Yoshinari T; GO-FORTH study group.	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.	Mod. Rheumatol.	26(4)	481-490	2016
Sakai R, Hirano F, Kihara M, Yokoyama W, Yamazaki H, Harada S, Nanki T, Koike R, Miyasaka N, <u>Harigai M</u> .	High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population based cross-sectional study of a Japanese health insurance database.	Mod. Rheumatol.	26(4)	522-528	2016
Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, <u>Miyasaka N</u> , Yamanaka H, Yamamoto K, Takeuchi T.	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomized, controlled study(SURPRISE study).	Ann. Rheum. Dis.	75(11)	1917-1923	2016
Matsuo Y, Mizoguchi F, Saito T, Kawahata K, Ueha S, Matsushima K, Inagaki Y, <u>Miyasaka N</u> , <u>Kohsaka H</u> .	Local fibroblast proliferation but not influx is responsible for synovial hyperplasia in a murine model of rheumatoid arthritis.	Biochem. Biophys. Res. Commun.	470(3)	504-509	2016
Yoshihashi-Nakazato Y, Kawahata K, Kimura N, <u>Miyasaka N</u> , <u>Kohsaka H</u> .	Interferon- $\gamma$ , but not interleukin-4, suppresses experimental polymyositis.	Arthritis Rheumatol.	68(6)	1505-1510	2016
Tanaka Y, Yamanaka H, Ishiguro N, <u>Miyasaka N</u> , Kawana K, Hiramatsu K, Takeuchi T.	Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.	RMD Open.	2016 Feb 18;2(1)		
Yamazaki H, Hirano F, Takeuchi T, Amano K, Kikuchi J, Kihara M, Yokoyama W, Sugihara T, Nagasaka K, Hagiyaama H, Nonomura Y, Sakai R, Tanaka M, Koike R, Nanki T, <u>Kohsaka H</u> , <u>Miyasaka N</u> , <u>Harigai M</u> .	Simplified disease activity index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan.	Mod. Rheumatol.	15	1-8	2016
Hirano F, Yokoyama W, Yamazaki H, Amano K, Hayashi T, Tamura N, Yasuda S, Dobashi H, Fujii T, Ito S, Kaneko Y, Matsui T, Okuda Y, Saito K, Suzuki F, Yoshimi R, Sakai R, Koike R, <u>Kohsaka H</u> , <u>Miyasaka N</u> , <u>Harigai M</u> ; T2T Epidemiological Study Group.	Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy.	Mod. Rheumatol.	21	1-9	2016

Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, <u>Miyasaka N</u> , Koike T.	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.	Ann Rheum Dis.	75(1)	75-83	2016
Tanaka Y, Takeuchi T, <u>Miyasaka N</u> , Sumida T, Mimori T, <u>Koike T</u> , Endo K, Mashino N, Yamamoto K.	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.	Mod Rheumatol. .	26(1)	80-86	2016
Tsuru T, Tanaka Y, Kishimoto M, Saito K, Yoshizawa S, Takasaki Y, Miyamura T, Niuro H, Morimoto S, Yamamoto J, Lledo-Garcia R, Shao J, Tatematsu S, Togo O, <u>Koike T</u> .	Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.	Mod Rheumatol.	26(1).	87-93	2016
Ikeda K, Narita A, Ogasawara M, Ohno S, Kawahito Y, Kawakami A, Ito H, Matsushita I, Suzuki T, Misaki K, Ogura T, Kamishima T, Seto Y, Nakahara R, Kaneko A, Nakamura T, Henmi M, Fukae J, Nishida K, Sumida T, <u>Koike T</u>	.Consensus-based identification of factors related to false-positives in ultrasound scanning of synovitis and tenosynovitis.	Mod Rheumatol.	26(1)	9-14	2016
Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K, Takenaka K, Soejima M, Sugihara T, Hagiyaama H, Hirata S, Matsui K, Nonomura Y, Kondo M, Suzuki F, Tomita M, Kihara M, Yokoyama W, Hirano F, Yamazaki H, Sakai R, Nanki T, Koike R, <u>Kohsaka H</u> , <u>Miyasaka N</u> , <u>Harigai M</u> .	Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.	Arthritis Res Ther	19(1)	7	2017
<u>Koike T</u> , <u>Harigai M</u> , Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Takasaki Y, Mimori T, Hiramatsu K, Komatsu S, Tanaka Y.	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals:Post Hoc Analysis of Japanese Patients (MELODY Study).	Rheumatol Ther	3(1)	129-141	2016
<u>Harigai M</u> , Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Watanabe M, Tamada H, <u>Koike T</u> .	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis	Mod Rheumatol	26(4)	491-8	2016